BKYI vs RTX

BIO-key International (BKYI) remains a highly speculative micro-cap with significant risk, yet shows nascent signs of a potential turnaround from a previously distressed state. While 2025 financial results presented declining revenue and continued net losses, the critical change is the preliminary Q1 2026 guidance projecting 37% YoY revenue growth and, more significantly, **expected cash flow posi...

RTX Corporation, a mega-cap aerospace and defense conglomerate, operates in a mature industry fundamentally unsuitable for 10x growth within a 3-5 year horizon. While demonstrating solid financial health with improving sales, adjusted EPS, and positive free cash flow ($7.9B in 2025, projected $8.25-$8.75B for 2026), and boasting a substantial $268B backlog, its sheer size ($270.55B market cap aimi...